au.\*:("SCHLEYERBACH R")
Results 1 to 23 of 23
Selection :
GLUCOSE TOLERANCE AND INSULIN SECRETION IN RABBITS AND DOGS AFTER LIGATION OF THE PANCREATIC DUCTS = TOLERANCE AU GLUCOSE ET SECRETION D'INSULINE CHEZ DES LAPINS ET DES CHIENS APRES LIGATURE DES CANAUX PANCREATIQUESHEPTNER W; NEUBAUER HP; SCHLEYERBACH R et al.1974; DIABETOLOGIA; ALLEM.; DA. 1974; VOL. 10; NO 3; PP. 193-196; BIBL. 18REF.Article
STUDIES ON THE EFFECT OF TOLBUTAMIDE, GLIBENCAMIDE, HB 699, AND GLUCOSE ON SERUM INSULIN AND BLOOD GLUCOSE IN GASTRO-ENTERECTOMIZED DOGSBICKEL M; GEISEN K; SCHLEYERBACH R et al.1978; ARCH. INTERNATION. PHARMACODYN. THERAP.; BEL; DA. 1978; VOL. 234; NO 1; PP. 118-138; BIBL. 2 P.Article
DIE ROLLE DER LEBER BEIM SOGENANNTEN RESORPTIONSDEFIZIT. ERGEBNISSE TIEREXPERIMENTELLER UNTERSUCHUNGEN. = LE ROLE DU FOIE DANS LE DEFICIT DIT DE RESORPTION. RESULTATS D'ETUDES EXPERIMENTALES CHEZ L'ANIMALBRETTEL HF; RUPP W; SCHLEYERBACH R et al.1977; Z. RECHTSMED.; DTSCH.; DA. 1977; VOL. 79; NO 3; PP. 217-223; ABS. ANGL.; BIBL. 7 REF.Article
NEUE ERKENNTNISSE IN DER SUBSTITUTIONSTHERAPIE MIT VERDAUUNGSENZYMEN = NOUVELLES CONNAISSANCES SUR LA THERAPEUTIQUE DE SUBSTITUTION PAR DES ENZYMES DIGESTIFSNEUBAUER HP; FUELBERTH W; RUPP W et al.1979; ARZNEIMITTEL-FORSCH.; DEU; DA. 1979; VOL. 29; NO 11; PP. 1733-1736; ABS. ENG; BIBL. 17 REF.Article
EIN NEUES MODELL ZUR ERFASSUNG DES HEPATISCHEN FIRST-PASS-EFFEKTS. = UN NOUVEAU MODELE POUR L'EVALUATION DE L'EFFET DE PREMIER PASSAGE HEPATIQUEBICKEL M; BRETTEL HF; JUNG S et al.1977; ARZNEIMITTEL-FORSCH.; DTSCH.; DA. 1977; VOL. 27; NO 10; PP. 1879-1881; ABS. ANGL.; BIBL. 17 REF.Article
Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity. I: Disease modifying action on adjuvant arthritis of the ratBARTLETT, R. R; SCHLEYERBACH, R.International journal of immunopharmacology. 1985, Vol 7, Num 1, pp 7-18, issn 0192-0561Article
Derivatives of leflunomide's active metabolite A77-1726, the malononitrilamides (mnas), prevent the development of experimental arthritisSCHORLEMMER, H. U; SCHLEYERBACH, R.International journal of immunotherapy. 1998, Vol 14, Num 4, pp 177-184, issn 0255-9625Article
Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the ratCASPRITZ, G; ALPERMANN, H. G; SCHLEYERBACH, R et al.Arzneimittel-Forschung. 1986, Vol 36, Num 11, pp 1605-1608, issn 0004-4172Article
A77-1726, leflunomide's active metabolite, inhibits in vivo lymphoproliferation in the popliteal lymph node assaySCHORLEMMER, H. U; KURRLE, R; SCHLEYERBACH, R et al.International journal of immunotherapy. 1998, Vol 14, Num 4, pp 205-211, issn 0255-9625Article
Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritisSCHORLEMMER, H. U; BARTLETT, R. R; SCHLEYERBACH, R et al.Transplantation proceedings. 1998, Vol 30, Num 8, pp 4137-4139, issn 0041-1345Conference Paper
Leflunomide's active metabolite A77-1726 and its derivatives, the malononitrilamides, inhibit the generation of oxygen radicals in mononuclear phagocytesSCHORLEMMER, H. U; KURRLE, R; SCHLEYERBACH, R et al.International journal of immunotherapy. 1998, Vol 14, Num 4, pp 213-222, issn 0255-9625Article
Effects of leflunomide on the course of listeriosis in miceHIRSCHELMANN, R; STEFFELDT, D; WILHELMS, D et al.Arzneimittel-Forschung. 1995, Vol 45, Num 5, pp 614-616, issn 0004-4172Article
Pharmacological profile of A85 4777, a novel antiiflammatory agent with nonclassical immunosuppressive propertiesBARTLETT, R. R; SCHLEYERBACH, R; SCHORLEMMER, K.-U et al.Transplantation proceedings. 1990, Vol 22, Num 4, pp 1666-1670, issn 0041-1345, 5 p.Conference Paper
Immunosuppressive activity of 15-deoxyspergualin (15-DOS) on various models of rheumatoid arthritisSCHORLEMMER, H. U; BARTLETT, R. R; SCHLEYERBACH, R et al.Drugs under experimental and clinical research. 1991, Vol 17, Num 10-11, pp 471-484, issn 0378-6501Article
Leflunomide : an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseasesHERRMANN, M. L; SCHLEYERBACH, R; KIRSCHBAUM, B. J et al.Immunopharmacology (New York). 2000, Vol 47, Num 2-3, pp 273-289, issn 0162-3109Article
Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in ratsTHOENES, G. H; SITTER, T; LANGER, K. H et al.International journal of immunopharmacology. 1989, Vol 11, Num 8, pp 921-929, issn 0192-0561Article
Effects of leflunomide on immune responses and models of inflammationBARTLETT, R. R; ANAGNOSTOPULOS, H; ZIELINSKI, T et al.Springer seminars in immunopathology. 1993, Vol 14, Num 4, pp 381-394, issn 0344-4325Article
Immunosuppressive therapy of experimental autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus by 15-deoxyspergualinSCHORLEMMER, H. U; BARTLETT, R. R; SCHLEYERBACH, R et al.International journal of immunotherapy. 1989, Vol 5, Num 1, pp 9-20, issn 0255-9625Article
De novo pyrimidine biosynthesis in jurkat T-cells is inhibited by leflunomide's primary metabolite A77-1726 at the level of dihydroorotate-dehydrogenase (DHODH)SCHORLEMMER, H. U; MILBERT, U; HAUN, G et al.International journal of immunotherapy. 1998, Vol 14, Num 4, pp 193-204, issn 0255-9625Article
Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejectionBARTLETT, R. R; DIMITRIJEVIC, M; FINNEGAN, A et al.Agents and actions. 1991, Vol 32, Num 1-2, pp 10-21, issn 0065-4299, 12 p.Conference Paper
Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agentKÜCHIE, C. C. A; THOENES, G. H; LANGER, K. H et al.Transplantation proceedings. 1991, Vol 23, Num 1, pp 1083-1086, issn 0041-1345, 2Conference Paper
Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomideGLANT, T. T; MIKECZ, K; BARTLETT, R. R et al.Immunopharmacology (New York). 1992, Vol 23, Num 2, pp 105-116, issn 0162-3109Article
